Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Gene signatures and stromal TILs in stage I triple-negative breast cancer

Paolo Tarantino • 1 Jun 2025
ASCO 2025
Breast Cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses associations between immune and proliferation gene signatures, stromal tumor-infiltrating lymphocytes (sTILs), and recurrence-free survival in patients with stage I triple-negative breast cancer or ER-low tumors, based on data from a single-center cohort. Higher immune signature scores and elevated sTIL levels were linked to numerically better outcomes, while higher proliferation scores correlated with worse prognosis. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Tarantino

Treatment options for advanced breast cancer: navigating the complex world of ADCs
1:14
Treatment options for advanced breast cancer: navigating the complex world of ADCs
Paolo Tarantino • 1 Jun 2025
DATO-Base: investigating Dato-DXd in HER2- breast cancer brain metastases
1:02
DATO-Base: investigating Dato-DXd in HER2- breast cancer brain metastases
Paolo Tarantino • 1 Jun 2025
Predictive biomarkers for T-DXd response in metastatic breast cancer
1:18
Predictive biomarkers for T-DXd response in metastatic breast cancer
Paolo Tarantino • 1 Jun 2025
Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
2:24
Breast cancer at ASCO 2023: NATALEE and sequencing ADCs
Paolo Tarantino • 5 Jun 2023

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals